(Reuters) – The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie’s drug, Restasis, to increase tear production in patients with dry eye syndrome.
The regulator has given the approval to Mylan Pharmaceuticals Inc.
(Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri)
